Related Experiment Video
Updated: May 14, 2026
07:22
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Short-term changes in plasma glucose affect glycated hemoglobin measurement
Richeek Pradhan1, Sandip Kumar Batabyal, Subrata Maiti
1Department of Pharmacology, Institute of Post-Graduate Medical Education and Research, Kolkata, India.
Diabetes Research and Clinical Practice
|February 5, 2013
Summary
A 12-hour delay between sample collection and hemoglobin A1c (HbA1c) measurement can impact results. An easy method is proposed to check for adequate removal of HbA1d, suggesting HbA1c re-measurement if needed.
Area of Science:
- Clinical Chemistry
- Diabetes Diagnostics
- Laboratory Medicine
Background:
- Hemoglobin A1c (HbA1c) is a key biomarker for long-term glycemic control in diabetes management.
- Pre-analytical variables, such as sample collection-to-measurement delay, can affect HbA1c assay accuracy.
- Understanding the impact of sample handling is crucial for reliable diagnostic results.
Purpose of the Study:
- To evaluate the effect of a 12-hour pre-analytical delay on HbA1c measurements.
- To develop a simple method for assessing the adequacy of HbA1d removal.
- To provide guidance on HbA1c testing following sample collection delays.
Main Methods:
- Investigating the impact of a 12-hour delay on HbA1c levels.
- Developing and validating a method to determine the sufficiency of HbA1d removal.
- Comparing HbA1c results obtained after different sample handling procedures.
Main Results:
- A delay of 12 hours between sample collection and HbA1c measurement can influence results.
- An effective method was identified to assess the removal of HbA1d.
- Insufficient HbA1d removal necessitates re-testing.
Conclusions:
- The timing of HbA1c measurement post-sample collection is critical for accuracy.
- The proposed method offers a practical approach to ensure reliable HbA1c results.
- Clinical laboratories should consider implementing this method to mitigate pre-analytical errors.
More Related Videos
Related Concept Videos
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...